Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Stryker Corporation — how do they compare? ProShares UltraPro Short QQQ ETF trades at $33.02 (market cap $2.23B), while Stryker Corporation trades at $277.22 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 47.6× ProShares UltraPro Short QQQ ETF's market cap, and Stryker Corporation pays a 1.27% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and Stryker Corporation for 21 Days on average.
| SQQQ | SYK | |
|---|---|---|
Market Cap | $2.23B | $106.24B |
Volume | 60,436,012 | 2,982,001 |
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $388.35 |
52-Week Low | $31.83 | $269.75 |
Typical Hold Time | 12 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.02, up 2.93% on the day. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral momentum. As a 3x leveraged inverse ETF designed to profit from Nasdaq 100 declines, SQQQ's performance is directly tied to technology sector weakness. Recent news highlights its potential role as a hedging tool against QQQ holdings during market downturns.
The outlook for SQQQ depends heavily on technology sector performance, with potential gains during Nasdaq 100 declines but significant decay risk during sustained rallies. Investors face substantial volatility risks due to daily rebalancing and compounding effects. Current market conditions suggest continued uncertainty for tech stocks, potentially supporting SQQQ's short-term appeal as a tactical hedge.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
